In Q1-Q3 2024, Ryvu recognized total operating revenues (including grants) of USD 18.6 million, compared to USD 11.9 million in Q1-Q3 2023.
Ryvu reports an acceleration in patient enrollment for its RVU120 Phase II clinical studies, attributed in part to a significant increase in the number of activated clinical sites. As of October 31, a total of 66 sites have been activated in the most advanced RIVER-81 and RIVER-52 studies, and this number is expected to grow further by the end of the year.
The Investor Event focusing on the progress and data update of RVU120 Phase II studies is scheduled for December 12 at 10:00 AM CET.
As of November 4, 2024, Ryvu’s cash position was USD 58.1 million. Together with other already secured funding sources, this cash position provides a runway through Q1 2026.
